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ABSTRACT 
Breast cancer incidence has, on average increased by 1.4 % annually during the last decades. 
Early detection and advances in treatment are the main contributing factors for the favourable 
outcome in terms of five- and ten-year survival rates. The biological factors that influence 
disease progression and mortality in breast cancer have been well studied. Comparatively less 
is known about the overall coping ability and their relevance for outcome in the breast 
cancer-population. The concept of sense of coherence (SOC) reflects a person´s orientation to 
life and was established to describe why people remain healthy during times of considerable 
strain, and manage to make sense out of difficult experiences or situations. In the current 
thesis SOC is measured by the Sense of Coherence Scale (SOC-13).  It contains 13 items that 
reflects the three core components; comprehensibility, manageability and meaningfulness. 
Higher SOC scores indicate higher sense of coherence.  
The main aim of the thesis was to evaluate the SOC scale´s stability and predictive value 
regarding progression and mortality in breast cancer patients. This was done utilizing a 
prospective design with a long-term follow-up in a multicenter cohort at four different 
Swedish hospitals. Two studies were performed. Of the total cohort, 75% and 87% 
respectively, participated in the two studies. 
In paper I, support for the SOC scale´s stability over time (ICC 0.68, effect size 0.06) was 
demonstrated. The result of the cross-sectional factor analysis revealed a modiﬁed three-
factor and a second order factor model meeting criteria for goodness of ﬁt. The longitudinal 
modiﬁed second-order factor model conﬁrmed the construct stability character of the SOC 
scale with an acceptable goodness-of-ﬁt criteria. 
In paper II, patients with high SOC had a 60% lower risk of breast cancer progression and a 
80% lower risk of mortality than patients with low SOC over a median follow-up time of 10 
years. The mortality risk declined by 2.3% for every one-unit increase in SOC (breast cancer 
mortality HR, 0.98; 95% CI, 0.96 to 0.99 and all-cause mortality HR, 0.98; 95% CI, 0.96 to 
0.99). After adjusting for potential cofounders, the risk declined by 1.7% (breast cancer 
mortality) and 1.5% (all-cause mortality). The risk of progression declined by 1.4% for every 
one-unit increase in SOC (HR, 0.99; 95% CI, 0.97 to 1.00). After adjusting for potential 
cofounders, the decline was 0.7%.  
In conclusion, the results from this thesis have shown that the SOC scale and its underlying 
construct is stable over time when applied to women with breast cancer. In addition, the SOC 
scale demonstrates a predictive value for disease progression, breast cancer caused mortality 
and for all-cause mortality among women with breast cancer and can be a valuable 
instrument for assessment of women at risk. 
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1 BACKGROUND 
1.1 BREAST CANCER 
Worldwide more than 1.2 million women are diagnosed with breast cancer every year, 
making it the second most common cancer form after lung cancer (1). In the Western 
hemisphere, breast cancer is the most common cancer among women. In Sweden, one in 
every eight women will get a breast cancer diagnosis during her lifetime and 8691 invasive 
breast cancer cases were diagnosed in Sweden 2014 (2). Sex and age are the most important 
determinants of breast cancer incidence. In Sweden, the mean age of onset is 64 years (2). 
The average annual increase in breast cancer has been 1.4% during the last two decades, with 
an increase from 80 to 200/100 000 female inhabitants from 1970 to 2014 (2). Both in 
Sweden and worldwide, lifestyle changes, such as women having fewer children, improved 
diagnostic methods, screening programs, and an ageing populations contribute to the increase 
(1).  
1.2 TREATMENT AND PROGNOSIS 
Sweden has national and regional evidence based treatment guidelines for breast cancer that 
are regularly updated in line with internationally accepted counterparts (3, 4). The primary 
treatment for the majority of patients is surgery. In addition, based on prognostic and 
treatment predictive information, radiotherapy and adjuvant systemic therapy (anti hormonal 
therapy, chemotherapy and anti-HER2 therapy) is recommended (3, 4). The definition of a 
disease prognostic factor is that it prognosticates the progression of untreated disease. A 
treatment predictive factor predicts the most likely therapy response to a certain therapeutic 
agent. Factors that provide prognostic and/or treatment predictive information for breast 
cancer are patient´s age, tumor stage according to TNM classification (T = tumor size and 
invasiveness, N = lymph node metastases, M = distant metastases) (4). In addition, tumor 
characteristics such as histological grade, expression of biomarkers, estrogen, progesterone 
receptor status, human epidermal growth factor receptor 2 statuses (HER2) also have 
prognostic and/or predictive value. More recently molecular sub typing of tumors has been 
introduced as valuable prognosticators (4). 
Post treatment follow-up varies according to risk group and whether the patient is included in 
any study protocol (4). Most women are referred back to the screening program after 
completion of adjuvant treatment. The routinely yearly clinical visits are almost non existing 
based on lack of evidence for such follow-up methods. The results of breast cancer treatment 
in Sweden measured as survival are among the best in Europe (1). Advances in medical 
knowledge and technology have reduced the adverse side effects of therapy (5). Long-term 
prognosis of breast cancer patients has improved significantly over the last 50 years (1). 
Breast cancer mortality in Sweden has, contrary to the incidence, been stable for many years 
with about 1 400 deaths per year but now decreases slightly by in average of 1% per year for 
the last 20 years (6). Breast cancer was up to 2005 the leading cancer causing death among 
women (6). Just about 94 000 individuals in Sweden live with a breast cancer diagnosis (7). 
Of those alive, over 83% live 10 years after diagnosis, making breast cancer patients the 
largest group of long-term cancer survivors (7). This situation also holds true for other 
countries with the best outcome (1). The improved survival is partly due to earlier detection 
and more targeted treatment (8). Despite this, a breast cancer diagnosis remains stressful for 
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most patients (9, 10) and stress may be associated with an elevated risk of breast cancer 
recurrence (11) and earlier mortality (12).  
1.3 SENSE OF COHERENCE (SOC) 
The medical sociologist Aaron Antonovsky conceptualized Sense of Coherence (SOC). This 
concept reflects a person´s orientation to life and was described as an attempt to explain why 
some people remain healthy during times of considerable strain, while other people become 
sick or ill under the same degree of strain (13, 14). Antonovsky studied a group of survivors 
from the concentration camps of the Second World War. He was intrigued and raised the 
question why these individuals, regardless of major stressful situations and severe hardships, 
were able to stay healthy. He postulated that it was because of the way they viewed their life 
and their essence of existence (14). SOC is defined as a global orientation that expresses the 
extent to which one has a pervasive, enduring though dynamic feeling of confidence (14). 
The SOC concept contains three components: comprehensibility, manageability and 
meaningfulness, which together contribute to the unity of SOC. These three components in 
the construct are dynamically interrelated, and serve as an overall coping resource (14). The 
SOC construct does not refer to specific types of coping strategies. It is intended to be a 
prerequisite for the perception and management to overcome a stressful situation (15). 
According to Antonovsky, people with high SOC possess resources that enable them to cope 
with various kinds of stressful life events. A person with a high feeling of comprehensibility 
expects that stimuli/ events that appear in the future will be rational, understandable and 
predictable, or if they come as surprises; they will be ordered and explicable (14). A person 
with high feeling of manageability perceives the resources as adequate and available to meet 
the demands posed by the stimulus, and still feels able to cope adequately with the situation. 
Finally, a person with high feeling of meaningfulness is more likely to feel that life makes 
sense and that at least some of the problems and demands are worth investing energy in and 
worth making commitments for (14). 
1.4 THE SOC SCALE 
Antonovsky developed the SOC scale, a self-report inventory, also called the Orientation to 
Life Questionnaire. The original SOC scale consists of 29 items (SOC-29), a shorter form has 
13 items (SOC-13) (14). The 13-item version has shown to be as reliable and valid as the 29-
item version (16-18). The items of the SOC-13 measure comprehensibility (5 items), 
manageability (4 items) and meaningfulness (4 items). An example of an item in the 
component of comprehensibility is “Do you have the feeling that you are in an unfamiliar 
situation and do not know what to do?” An example of an item in the component of 
manageability is, “How often do you have feelings that you are not sure you can keep under 
control?” and of an item in the component of meaningfulness is, “Do you have the feeling 
that you do not really care about what goes on around you?” The SOC scales have been 
validated in several settings using cohorts both from within healthcare facilities and from 
general populations. Reliability and validity have been supported in numerous studies, 
including cancer populations (19-21), with internal consistency, with Cronbach´s alpha 
ranging from  0.74 to 0.93 (16). There are no predefined boundaries for high and low SOC 
respectively (16). A review summarized the research on the SOC scales until 1992 and 
reported data from 42 different studies (22) and another review analyzed studies from 1992 to 
2003 (16). The SOC scales have been widely used in 127 cross-sectional and longitudinal 
studies with up to 20 000 persons (16). The SOC scales have been used in both Western 
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countries, including Sweden, and in Japan, China, Thailand and South Africa. They are 
validated for more than 33 languages in 32 countries. Thus, the SOC-13 scale is considered to 
be cross culturally applicable (16).  
Over the years, the concept of SOC has become well established in public health, in health 
promotion and has received attention within healthcare research. Antonovsky suggested that 
one of the most crucial determinants in an individual´s perception of health is the degree of 
SOC which will have a health-protective behavior pattern and a stress buffering effect (13). 
Longitudinal studies have supported Antonovsky´s view of the SOC construct as a health-
promoting factor (23-26), for both physical (25, 27) and mental well-being (28, 29). Eriksson 
and Lindström conclude in their review that the SOC scale shows high predictability for 
health in both the short- (months) and long-term (years) perspective (30). Also, higher 
degrees of SOC correlates with better self-rated health (21), less chronic disease risk factors 
(31), better quality of life (32), less prevalence of symptoms (33), less distress (34, 35), better 
adaptation to a life situation during a disease regardless of disease severity (21, 33, 36) and 
improved survival (27). 
1.5 THE STABILITY OF SOC 
Antonovsky considered that SOC represents a stable dispositional orientation; it develops 
through young adulthood when it stabilizes and remains relatively stable and only fluctuates 
temporary when radical life events occur (14). This is supported by several studies (17, 37-
41). Eriksson and Lindström confirm in a review that variations over time are small in adults 
(16). However, some studies have questioned the stability of SOC as stated by Antonovsky 
and propose that SOC depends on a person´s physical and mental state that can change over 
time (42, 43). Others have claimed that a low SOC score mainly reflects psychiatric 
morbidity such as anxiety or depression (44, 45). While other studies suggest that high SOC 
represents more than just the absence of psychopathology (39, 46). 
1.6 SOC AND BREAST CANCER 
Gibson and Parker found in their study of breast cancer survivors that SOC was a direct 
predictor of psychological well-being (47). Among 100 patients who had undergone surgery, 
including some breast cancer surgery, showed that high SOC was positively related to less 
pain and distress (48). Several studies have concluded that SOC significantly predicts better 
health status, less distress regardless of disease stage or treatment (21) and lower levels of 
symptom burden (33, 49) in women with breast cancer. A study by Boman et al. found that 
higher SOC was associated with better-perceived general health and mental well-being short 
term after breast cancer surgery (50). Studies have also shown that a higher SOC in breast 
cancer patients correlated statistically significantly with health related quality of life (21, 51-
53). Although several studies have been performed during the course of the breast cancer 
disease, neither of them has evaluated SOC´s stability over time in this group, nor the 
stability of SOC´s construct. 
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1.7 SOC, PROGESSION AND MORTALITY 
Although the biological factors that influence disease progression and mortality in cancer 
have been well studied, comparatively less is known about the coping abilities influence on 
outcomes in cancer populations. Only one previous study has examined SOC´s prediction of 
cancer progression. In a sample of 16 patients with acute leukemia and highly malignant 
lymphoma, patients who did not relapse had a significant higher SOC than those with 
recurrences during a 2-year study period (54). One study evaluated SOC´s association with 
cancer incidence and reported an increased overall cancer incidence in a cohort of 5800 men 
with low SOC. This led to the assumption that a high SOC could putatively delay the onset of 
cancer (55). Surtees et.al examined SOC´s predictive value for overall cancer mortality and 
found that a higher SOC was associated with 30% reduced cancer mortality in men (56). 
However, a high SOC did not improve survival in head and neck cancer (57). A few 
population-based studies report that higher SOC was associated with a decreased risk of all-
cause mortality (27, 56, 58-61). However, there are also studies diverging from these results. 
Lundman et al. found a significant association with 1-year mortality, but not with 4-year 
mortality among participants above 85 years of age (59). Haukkla et al. found that the 
association between higher SOC and a lower risk of all-cause mortality became non 
statistically significant after adjustment for depressive symptoms (62). No study has yet 
examined SOC´s prediction on progression, breast cancer mortality and all-cause mortality 
among breast cancer patients. 
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2 AIMS  
The main aim was to extend the knowledge of the SOC scale´s stability and predictive value 
with regards to progression and mortality in breast cancer patients.  
 
The specific aims were: 
1. To test the stability of the SOC scale over time and to test the stability of the latent 
construct in patients with breast cancer from the time of diagnosis (preoperatively) to one 
year postoperatively, and in a subsample two and three years postoperatively. 
 
2. To pursue the SOC scale’s predictive value in breast cancer patients with regards to 
progression and mortality in long term (a median follow up time of 10 years). 
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3 MATERIAL AND METHODS 
The design was a longitudinal prospective cohort study. An overview of subjects and 
methods (study I and II) is presented in Table 1. 
Table 1. Overview of Subjects and Methods   
  Study I Study II 
Study Design Longitudinal prospective cohort 
study 
Longitudinal prospective cohort 
study 
Sample Women with invasive breast cancer 
included in the multicenter trial 
who answered SOC-13 at T1 and 
T2 (n=417) and a subsample 
(n=80) who answered SOC-13 
additionally at T3 and T4 
Women with invasive breast cancer 
included in the multicenter trial 
who answered SOC-13 at T1 
(n=487) 
Data Sources SOC-13, medical charts, the 
Swedish Cancer Registry 
SOC-13, medical charts, the 
Swedish Cancer Registry, the 
Swedish Cause of Death Registry  
Inclusion period 1999- 2004 1999- 2004 
Follow-up period 1999- 2007 1999- 2012 
Outcome SOC stability  SOC´s predictive value for breast 
cancer progress and mortality 
3.1 SAMPLE 
The patient cohort originates from a Swedish multicenter trial that recruited patients from 
four breast cancer units at three university hospitals and at one county university-affiliated 
hospital. The primary aim of the study was to assess subjective and objective arm morbidity, 
health related quality of life and SOC after different surgical procedures of breast cancer at 
the time of introducing the sentinel node biopsy concept (63, 64). The participating units 
performed 4283 breast cancer operations on patients potentially eligible for the study during 
the time of data collection (1999-2004). Postoperative adjuvant treatment (chemotherapy, 
radiotherapy and hormonal treatment) was given according to the national guidelines. 
The patients were included consecutively. The study cohort included 557 women with 
invasive breast cancer. In addition to the surgical procedure, eligible patients had undergone 
either sentinel node biopsy or axillary lymph node dissection. Exclusion criteria were 
difficulties in understanding the Swedish language, mental or physical inability to participate 
in the pre- and postoperative evaluation, bilateral breast cancer, previous axillary treatment or 
clinically fixed axillary metastases. 
The recruitment process for the two studies is described in Figure 1. Those 417 patients 
(75%) who answered a complete SOC scale both preoperatively (T1) and 1 year 
postoperatively (T2) formed the main cohort of study I and a sub cohort consisting of 80 
patients from one of the study sites (university hospital) was evaluated additionally two (T3) 
and three (T4) years postoperatively. Those 487 (87%) of the included patients who answered 
the complete SOC scale preoperatively formed the cohort of study II.  
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Figure 1 Number of women included in the study. T1 = preoperative, T2 = one year 
postoperative, T3= two years postoperative, T4= three years postoperative. 
3.2 DATA COLLECTION 
Demographic data (including age, employment and marital status at surgery), and medical 
data (including type of breast surgery, tumor size, lymph node status and type of adjuvant 
treatment given) were collected from medical charts and recorded.  
Data on disease progression (including first local/regional/distant event) was obtained from 
the National Cancer Registry (65). It has since 1958 covered the whole population and 
approximately 60 000 malignant cases of cancer are registered every year in Sweden. Since 
the mid-80’s six regional registries are associated with the Regional Cancer Centers in 
Sweden, where coding, major check-up and correction work is performed. The estimated 
underreporting of the coverage rate in comparison to the inpatient registry is approximately 
4% (66, 67). 
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Mortality data (including date and cause of death) was obtained from the Cause of Death 
Registry (6). It has since 1961 provided the basis for the official statistics on cause of death 
in Sweden and is updated every year. 
SOC was assessed using the Swedish version of the self-assessment questionnaire, SOC-13 as 
shown in appendix. After informed consent had been provided by the patients, the study-
affiliated nurses at each of the participating centers handed out the SOC scale before surgery 
(study I and II) and during follow-up visits (one, two and three years postoperatively) (study 
I). The SOC-13 scale has a semantic-differential format ranging from one to seven points 
with two anchoring responses (for example never and very often). Five of the items are 
formulated negatively and have to be reversed in scoring, so that a high score always 
expresses a high SOC. After reversing the scores, a total sum score, ranging from 13 to 91, is 
obtained. Higher SOC scores indicate a higher sense of coherence. 
3.3 STATISTICAL ANALYSIS 
The statistical methods used in study I and II, their functions and criteria are described in 
Table 2. In all analyses, a p value < 0.05 was regarded as statistically significant. 
Table 2. Statistical methods      
Method   Function Criteria 
Descriptive statistics: 
mean, SD, range, 
percentage  
Studies I-II Describe demographic and 
clinical data of the study cohort 
 
Cronbach´s alpha 
reliability coefficient  
Study I Test the reliability of SOC-13 ≥ 0.70 is satisfactory 
Student´s t-test, ANOVA, 
Intra-class correlation 
(ICC), Cohen´s effect size  
Study I Analyse differences in SOC´s 
mean value over time 
ICC; < 0.4 is poor, 0.4 to 0.75 
is moderate, > 0.75 is good 
agreement. Cohens effect size; 
d= 0.20 is small, d = 0.50 is 
medium, d = 0.80 is large. 
Cross-sectional factor 
analysis, Chi-square test  
Study I Explore the theoretical 
construct of the SOC-13 scale 
by goodness of fit 
Criteria of goodness of fit: 
X²/dƒ ratio (criteria < 3), GFI 
(criteria ≥ 0.90), RMSEA 
(criteria < 0.08), CFI (criteria ≥ 
0.90).  
Longitudinal factor 
analysis, Chi-square test  
Study I Assess the construct stability 
character of SOC-13 by 
goodness of fit 
Criteria of goodness of fit: 
X²/dƒ ratio (criteria < 3), GFI 
(criteria ≥ 0.90), RMSEA 
(criteria < 0.08), CFI (criteria ≥ 
0.90). R² ≥ 0.40 is satisfactory. 
Cut off level for factor loading 
is > 0.40. 
Univariate and 
multivariate analyses 
Study II Identify significant 
independent predictors for 
progress and mortality 
 
Cox proportional-hazard 
regression  
Study II Estimate hazard ratios 
associated with increasing 
SOC over time 
 
Logistic Regression  Study II Estimation of probability of 
progress or mortality  
 
Receiver operating 
characteristic (ROC) 
analyses 
Study II Assess sensitivity and 
specificity of the logistic 
regression 
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3.3.1 Study I 
The descriptive statistics was used to characterize the demographic and clinical data of the 
study cohort. When evaluating the Cronbach’s alpha reliability coefficient of the SOC scale, a 
Cronbach’s alpha coefficient equal to or greater than 0.70 was considered satisfactory (68).  
3.3.1.1 Test-retest 
The student’s t-test was used to analyze the differences in mean values over time in the main 
sample. Analysis of variance (ANOVA) was used to analyze the differences in mean values 
over time in the sub cohort, and in addition to that intra-class correlation coefficient (ICC). 
As suggested (69), ICC is interpreted to be poor <0.4, moderate 0.4 to 0.75, or good 
agreement >0.75. Cohen’s effect size was used to evaluate the clinical relevance of mean 
changes between the two time points and according to Cohen (70), d = 0.20 indicates a small; 
d = 0.50 a medium; and d = 0.80 a large effect-size. 
3.3.1.2 Factor analyses 
When further assessing the SOC scale´s stability, cross sectional and longitudinal factor 
analysis models were used, based on the 417 patients in the main cohort. The theoretical 
construct was analyzed cross-sectionally separately for the two time points (T1 and T2) in 
three steps: one-factor, three-factor and second-order factor models, in accordance with 
earlier studies and Antonovsky’s theoretical modeling (14, 17, 18).  
By combining the cross-sectional models together with evaluation of the stability of the 
hypothetical underlying constructs, the longitudinal factor analysis models were created. The 
goodness-of-fit describes the factor models fit and were evaluated by Chi-square to the 
degrees of freedom ratio (criteria: ratio<3), goodness-of-fit index (GFI) (criteria: ≥0.90), 
comparative fit index (CFI) (criteria: ≥0.90) (71, 72) and root-mean square error of 
approximation (RMSEA) (criteria: <0.08) (71). The Akaike information criterion (AIC) is a 
measure of the relative quality of the factor models. A decrease in Akaike’s information 
criterion (AIC) is a sign of the improvements in the cross-sectional and longitudinal factor 
model fit (73). The squared multiple correlation (R
2
) indicates how well data fits in the 
statistical model and is thereby a prediction of future outcomes of the final longitudinal factor 
model. If the relation between the latent factors (i.e. SOC T1 and SOC T2) does not change 
over time (proportion of variance) the longitudinal factor analysis model fits (74). The 
squared multiple correlation (R
2
) equal to the proportion of variance at T2 explained by the 
estimation at T1. In line with recommendations based on previous research , a factor loading 
greater than 0.40 was used as cutoff level (70). R
2
 ≥0.40 is considered as satisfactory (72). 
The Statistical Packages of Social Sciences (SPSS) software (SPSS Inc., Chicago, IL, USA) 
for Windows (version 20), and the Analysis of Moment Structures (AMOS) structural 
equation modeling program version 16.0 were used for the analyses. 
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3.3.2 Study II 
Descriptive statistics were used for the demographic and clinical data of the study cohort. The 
breast cancer patients were followed from inclusion to tumor progression, death from breast 
cancer or death from all causes or end of study, whichever came first. The analyses were 
performed for each event separately. The definition of progression-free survival was the time 
elapsing from surgery to progression or to breast cancer caused death. Breast cancer survival 
and overall survival was defined as the time elapsing from surgery to death. End of follow up 
represented a censoring event. To assess progression-free survival and survival Kaplan-Meier 
survival curves were used in three equal sized groups of SOC. 
3.3.2.1 Cox proportional-hazard Regression 
To identify significant independent predictors, Cox proportional-hazard regression was used 
to estimate the effect of one-unit increase in SOC for the crude (univariate) and adjusted 
(multivariate) hazard ratios (HR and aHR). The means of natural cubic spline variables were 
assessed by the linearity of the relationship between the log-hazard and SOC. By including, a 
time-varying interaction between time and SOC, the assumption of proportional hazards was 
tested. Potential cofounders were identified through univariate analyses. The multivariate 
analysis included the following potential cofounders in the adjusted model in addition to 
SOC: age (26 to 51, 52 to 57, 58 to 65, 66 to 89 years), married/cohabitant (yes or no), 
employed (yes or no), breast surgery (breast-conserving surgery or mastectomy), lymph node 
status (positive or negative). To cross validate SOC as a predictor the recalibration coefficient 
was calculated for the estimates of the hazard ratio associated with one-unit increase in SOC 
with a thousand Monte Carlo bootstrap samples (75). 
3.3.2.2 Logistic Regression 
With logistic regression the probability of experiencing tumor progression, death of breast 
cancer, and death of all causes within 5 years after inclusion was estimated. No data were 
censored before this time period (i.e. follow-up time for the present study was 8-12 years). 
The sensitivity and specificity of the predictive model by receiver operating characteristic 
(ROC) analyses was summarized thus obtaining the area under the receiver operating 
characteristic curve (AUC). To quantify the predictive value of SOC per se, SOC was 
excluded but all the other predictors from the multivariate analysis were included. 
The Statistical Packages of Social Sciences (SPSS) software (SPSS Inc., Chicago, IL, USA) 
for Windows (version 20) and the statistical software Stata version 14 (Statacorp, College 
Station, TX) was used for all analyses. 
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3.4 ETHICAL CONSIDERATIONS 
The regional Ethics Committee approved study I and II (Dnr 500: 16 979/99, 2011 1916: 32 
and Dnr 500: 16 979/99, 2011 1916: 32). The researchers involved in these studies had no 
conflicts of interest.  
Enrollment followed WMA Declaration of Helsinki–Ethical Principles for Medical Research 
Involving Human Subjects. Patients were informed about the study and that participation or 
non-participation would not affect treatment and care. The ethical principle of respect for 
human dignity and justice includes the right to self-determination, full disclosure, fairness and 
privacy i.e. patients must be reassured that their decision is voluntary and without pressure 
when they are asked to participate in a study (76, 77).  
Participation in research can be agreed to for several reasons such as; hope for direct benefit 
from the study or that other patients can benefit from the research results in the future (76, 
77). In study I and II there were no obvious benefits for the participating patients. 
Furthermore, participating in study I and II was not considered harmful other than the burden 
the patients may feel when answering the self-assessment questionnaire.  
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4 RESULTS 
4.1 STUDY I 
The mean age of the study cohort (n=417) at inclusion was 58.8 years (SD 10.4, range 26-
89). Most were married or cohabiting and employed. The majority had breast-conserving 
surgery and had received at least one of the postoperative adjuvant therapies (chemotherapy, 
radiotherapy and/or anti hormonal treatment) (Table 3).  
The sub cohort (n=80) were statistically significantly younger (mean 56.6 years SD 8.8, range 
40–81 years vs. 58.8, SD 10.4, range 26–89 years). Fewer underwent breast conserving 
surgery (64 vs. 73 %), and also received radiotherapy less often (70 vs. 83 %). 
 
Table 3. Demographic and clinical data 
              
Characteristics 
   
Study I 
(n=417)   
 
Study I 
(n=80)    
Study II  
(n=487) 
Age* 
         Mean, (SD) 
 
58.8 (10.4)  
  
56.6 (9.8)
  
58.8 (10.6)  
Range 
  
26-89 
  
40-81 
  
26-89 
  
n %   n %  n % 
Married/Cohabitants* 
        Yes 
 
287 68.8
 
52 65.0
 
328 67.4 
No 
 
130 31.2 
 
28 35.0 
 
159 32.6 
Employed* 
        Yes 
 
209 66.3
 
58 72.5
 
284 58.3 
No 
 
106 33.7 
 
22 27.5 
 
203 41.7 
Breast surgery 
          Breast conserving surgery 
 
305 73.1
 
51 63.8
 
354 72.7 
Mastectomy 
 
112 26.9 
 
29 36.3 
 
133 27.3 
Tumor size 
         ≤ 20 mm 
 
284 68.1
 
53 66.3
 
319 65.5
21-50 mm 
 
122 29.3 
 
26 32.5 
 
155 31.8 
> 50 mm 
 
11 2.6 
 
1 1.3 
 
13 2.7 
Lymph node status 
        Negative 
 
285 68.3
 
52 65.0
 
320 65.7
Positive 
 
132 31.7 
 
28 35.0 
 
167 34.3 
Postoperative adjuvant treatment** 
      Antihormonal treatment 
        Yes 
 
323 77.5
 
62 77.5
 
378 77.6 
No 
 
94 22.5 
 
18 22.5 
 
109 22.4 
Chemotherapy 
        Yes 
 
153 36.7
 
33 41.3
 
183 37.6 
No 
 
264 63.3 
 
47 58.8 
 
304 62.4 
Radiotherapy 
        Yes 
 
346 83.0
 
56 70.0
 
409 84.0 
No 
 
71 17.0 
 
24 30.0 
 
78 16.0 
Disease progession*** 
        No 
 
329 78.9
 
68 85.0
 
386 79.3
Yes 
 
88 21.1 
 
12 15.0 
 
101 20.7 
Deceased*** 
        Breast cancer 
 
55 13.2
 
9 11.3
 
75 15.4
Another reason   14 3.4   1 1.3  21 4.3 
* At inclusion 
 
** More than one regime could be given 
 
*** 8-12years 
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4.1.1 Test-retest 
The mean SOC of the study cohort (n=417) at T1 was 70.9 (SD 10.3, range 42–90) and at T2 
70.2 (SD 11.4, range 33–91) (Fig 2). There was no significant difference in mean values 
between T1 and T2. The intra-class correlation coefficient (ICC) between the two time points 
was 0.68 and the effect size was 0.06.  
 
Figure 2. SOC sum (n=417) at T1 and T2. Data is presented with 25
th
 and 75
th
 percentile 
range in boxes, whiskers represent 10
th
 and 90
th
 percentiles and dots are outliers. 
The mean SOC values in the sub cohort (n=80) at T1 was 69.9 (SD 10.4, range 44–89), at T2 
71.1 (SD 11.0, range 33–91), at T3 72.3 (SD 11.2, range 39–90) and at T4 71.3 (SD 11.0, 
range 43–91). There was a significant difference (p = .026) in the sub cohort between T1 and 
T3 (Fig 3). The ICC in the sub cohort ranged from 0.68 to 0.74, and the effect size ranged 
from 0.10 to 0.21 during the four time points.  
Figure 3. SOC sum (n=80) at T1, T2, T3 and T4. Data is presented with 25
th
 and 75
th
 
percentile range in boxes, whiskers represent 10
th
 and 90
th
 percentiles and dots are 
outliers. 
  23 
Cronbach’s alpha at all measurement time points in both samples (n=417 and n=80) was 
above 0.80. 
4.1.2 Cross-sectional factor analysis 
To address the construct validity of SOC, a cross-sectional factor analysis was performed 
separately for T1 and T2. As seen in Table 4, the results showed that the one-factor, three-
factor and second-order factor models did not reach all the criteria of goodness-of-fit at the 
two time points. The main measurement errors occur mainly between the meaningfulness 
item 1 (“Do you have feeling that you don’t really care about what goes on around you?”), 
the comprehensibility item 2 (“Has it happened in the past that you were surprised by the 
behavior of people whom you thought you knew well?”) and the manageability item 3 (“Has 
it happened that people whom you counted on disappointed you?”) at T1 and T2 (Table 4 and 
5). All models improved after a modification of the models allowing correlation between 
measurement errors between items, both at T1 and T2. The three-factor and the second-order 
factor models met all criteria for model fit at the two time points. 
 
Illustration used with permission from Springer International Publishing and Journal of Quality of Life Research. All rights reserved. 
www.springer.com 
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4.1.3 Longitudinal factor analysis 
The stability of SOC was investigated by using longitudinal factor analysis models. As seen 
in Table 5, the models allowed correlation between measurement errors of the same items 
over time (T1→ T2). The model fit was improved. The last longitudinal modified second-
order factor model had a satisfactory goodness-of-fit. The Chi-square to the degrees of 
freedom ratio and RMSEA values met standard criteria, although the values of the fit indices 
GFI and CFI were slightly lower than the suggested fit levels. The last longitudinal modified 
second-order model showed the best goodness-of-fit of the data with the lowest Chi square 
and AIC.  
 
Illustration used with permission from Springer International Publishing and Journal of Quality of Life Research. All rights reserved. 
www.springer.com 
 
Finally, when comparing the longitudinal modified two-factor and second order factor 
models the result revealed that the factor loadings were similar in both models with 
standardized parameter estimates, at T1 between 0.26 and 0.81 and at T2 between 0.35 and 
0.78. Items 1, 2 and 3 had factor loadings < 0.40 at T1 and item 1 and 2 at T2. As seen in 
Figure 4, the correlation coefficient between the latent factors (i.e. SOC T1 and SOC T2) was 
0.65, and the proportion of variance in the final model was R
2
 = 0.42. 
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Figure 4. The longitudinal second-order factor model with standardized parameter 
estimates allowing correlations between measurement errors of the items at T1 and T2 
CO= Comprehensibility, ME= Meaningfulness, and MA=Manageability 
Illustration used with permission from Springer International Publishing and Journal of Quality of Life Research. All rights reserved. 
www.springer.com 
4.2 STUDY II 
The majority of the 487 woman had breast-conserving surgery. Two-thirds had a tumor size 
≤20 mm and no lymph node metastases. Most had received at least one of the postoperative 
adjuvant therapy regimens (chemotherapy, radiotherapy and/or anti hormonal treatment) 
(Table 3).  
The study cohort accumulated 4552.2 person-years of follow-up time in a median of 10- year 
follow-up. A total of 126 progressions were observed, with a rate of 0.030 tumor 
progressions/person-year (95% CI, 0.03 to 0.04). Seventy-five breast cancer caused deaths 
with a mortality rate of 0.016 deaths/ person-year (95% CI, 0.01 to 0.02) and 96 deaths from 
all causes with a mortality rate of 0.021 deaths/ person-year (95% CI, 0.02 to 0.03) occurred 
during the follow-up period. 
4.2.1 Progression-free survival, breast cancer survival and overall survival 
The mean SOC score of the study cohort at baseline (T1) was 67.2 (SD 13.4, range 20-90). 
Tumor progression was more prevalent in patients with the lowest SOC values. Breast cancer 
survival and overall survival was also lower in this group. The patients with higher SOC had 
a lower risk of progression and dying during the follow-up time. Compared with patients 
reporting low levels of SOC, those reporting high levels of SOC had a 60% reduced risk of 
breast cancer progression, and an 80% reduced risk of breast cancer and all-cause mortality in 
the 10-year follow up. 
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In the Cox proportional-hazard regression model, the spline variables were not significant, 
which provided evidence against a non-linear relationship between log-hazard and SOC. No 
evidence of lack of proportionality in the interaction between time and SOC was found. 
Results illustrated a declining risk of progression by 1.4% for every unit increase in SOC 
(HR, 0.99; 95% CI, 0.97 to 1.00). A slightly weaker association that became borderline 
statistically non-significant, when adjusted for the potential cofounders (high age, 
unmarried/not cohabitant, unemployed, having a mastectomy and having positive lymph 
nodes). The adjusted decline was 0.7% (aHR, 0.99; 95% CI, 0.98 to 1.01).  
For every unit increase in the SOC scale, the risk of dying (breast cancer caused mortality and 
all-cause mortality) declined by 2.3% for breast cancer mortality (HR, 0.98; 95% CI, 0.96 to 
0.99) and all-cause mortality (HR, 0.98; 95% CI, 0.96 to 0.99). When adjusted for potential 
cofounders, the statistically significant association persisted. The decline was then 1.7% 
(breast cancer) (aHR, 0.98; 95% CI, 0.97 to 1.00) and 1.5% (all-cause) (aHR, 0.99; 95% CI, 
0.97 to 1.00). 
The result of the ROC analyses showed that the AUC for five-year progression-free survival 
was 0.58 (95% CI, 0.51 to 0.65), with a cut-off value of SOC at 70. Sensitivity and specificity 
were 50.2% and 58.4% respectively. The AUC for five-year breast cancer and overall 
survival was 0.61 (95% CI, 0.52 to 0.70). With a cut-off value of SOC at 70, sensitivity and 
specificity were 50.0% and 62.2% respectively.  
When SOC was included in addition to the other predictors from the multivariate analysis, the 
risk of progression in 6.8 % of the patients (95% CI, 4.7% to 9.4 %) would be classified more 
accurately. Likewise having SOC included in the analysis showed a more accurate risk 
classification; both for the risk for breast cancer caused mortality in 23.8% (95% CI, 20.1% 
to 27.9%), and that of the risk for all-cause mortality in 17.5% (95% CI, 14.2% to 21.1%) of 
the patients.  
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5 DISCUSSION 
5.1 STUDY I 
The results support Antonovsky’s theory that the SOC scale is reflecting a trait by showing 
stability over time (14). However, it is possible that radical life-events might temporarily alter 
the individuals SOC (14, 40). This may be reflected in the present study where there was a 
minor but statistically significant difference in the sub cohort between T1 and T3. This 
difference was not observed at T4. The finding may reflect a temporary increase in SOC, 
indicating a transient state characterized by feeling of optimism and strength in these women 
who have recently gone through a life-threatening situation. The results concur with Eriksson 
and Lindström who postulate that SOC variations over time are small (16). In conclusion, no 
clinically significant SOC changes were found in mean values when measured one, two and 
three years postoperatively confirming the robustness of the SOC concept (17, 37-41).  
The study also supports Antonovsky’s theory by confirming the SOC structure’s stability in 
that the overall scale reflects one higher-order construct: comprising three dynamically 
interrelated components (i.e. comprehensibility, manageability and meaningfulness) (13, 14). 
The results give the strongest support for the longitudinal second-order factor model 
(although allowing correlation between measurement errors of some items) as the most 
adequate model in assessing the stability of sense of coherence at both time points. Similar 
findings have been detected in previous studies that examined the SOC scale´s factorial 
validity. They provide support for a stable second-order factor structure i.e. that the SOC 
scale reflects a single latent factor, although with a three-factor structure approximately or 
partly corresponding to comprehensibility, manageability and meaningfulness (16, 18, 78-
80), whereas others only support the one-factor structure (22, 81).  
The findings are also consistent with other studies in different populations and cultural 
settings. Lower factor loadings of item 1, 2 and 3 have been found (78). Further, misfit of 
item 1 was described in two Rasch analyses (82, 83) and finally measurement error 
correlations of items 2 and 3 have been reported (18, 78, 84). Future studies should calibrate 
the SOC scale for example by deleting item 1 to see if the factor structure improves or by 
using a scale with less scale steps as suggested by Holmefur et al (82). Also, future factorial 
analyses without item 2 are needed. The lower factor loadings and the correlated 
measurement errors of item 3 might depend on the misfit of item 2. 
5.2 STUDY II 
The current longitudinal prospective cohort study is the first to examine SOC´s prediction for 
breast cancer progression, mortality and all-cause mortality. The results show that breast 
cancer patients with higher SOC had a decreased risk of breast cancer caused mortality and 
all-cause mortality compared with those with lower SOC. The results are in line with the few 
population-based studies that have reported higher SOC to be associated with a decreased risk 
of all-cause mortality (27, 56, 58-61). Further, the results indicate that a higher SOC score is 
associated with decreased risk of breast cancer progression. However, the SOC as an 
independent predictor becomes non-significant when adjusted for other potential cofounders 
(high age, unmarried/not cohabitant, unemployed, having a mastectomy, and having positive 
lymph nodes), this may be associated with the sample size. As mentioned earlier, survival 
after breast cancer has improved, partly due to earlier detection and advances in treatment (8). 
Despite established prognostic factors such as; age, tumor stage, histological grade, 
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expression of receptors and biomarkers and gene expression (5), there are still variations in 
breast cancer prognosis that cannot be fully explained by the established prognostic factors. 
A link between low SOC and increased risk of breast cancer progression and mortality may 
be a bio-psychosocial pattern with a physiological stress response. The overall stress response 
involves activation of several body systems. Chronic stress may contribute to deleterious 
effects on regulation of the stress response systems as well as many organ systems (85). 
Major stressors may therefore be associated with an elevated risk of breast cancer (86, 87), 
recurrence (11) and earlier mortality (12). A breast cancer diagnosis is considered stressful 
for almost all patients (9, 10). According to Antonovsky, SOC does have a stress buffering 
effect and those with a high SOC possess resources that enable them to cope with various 
kind of stressful life experiences (14). There is evidence to support that a higher SOC 
correlates with less distress (21, 29, 30, 88). Antonovsky discussed high and low SOC, but 
did not define boundaries for a normal SOC (13, 14), and there is no consensus in the 
literature on what constitutes high, normal and low SOC (16). This needs to be considered 
when interpreting the results. Hypothetically, the patients with a lower SOC i.e. lower ability 
to manage life strains, experience life with or after breast cancer as more stressful and with 
more intense physiological stress response. This may contribute to a higher risk of tumor 
progression and breast cancer mortality. This possible connection between SOC, stress and 
breast cancer mortality needs to be further explored. 
Another link between low SOC and increased risk of breast cancer progression and mortality 
may be psychosocial factors. Studies have shown that depressive symptoms (89-91) and 
depressive or passive coping styles (92) are associated with increased mortality among cancer 
patients. Similar findings have been shown among breast cancer patients where depressive 
symptoms are associated with higher breast cancer mortality (93-95) and a decreased survival 
time among women with metastatic breast cancer (96). This link between depressive 
symptoms, breast cancer progression, and mortality may be due to modulation of the immune 
system (97, 98). Although SOC and mental health are interrelated, they are considered as 
independent concepts (30, 39). Previous studies support Antonovskys prediction that SOC is 
associated with successfully coping with life stress, psychological anxiety and depression (14, 
81, 99, 100). However, a study by Henje Blom et al. saw an inverse prediction (101) and in a 
study by Haukkla et al. the association between SOC and all-cause mortality became non 
statistically significant after adjustment for depressive symptoms (62). Psychosocial factors 
such as depressive symptoms and passive coping styles may be a link between SOC and 
breast cancer progression and mortality, trough physiological stress response and behavior 
pattern. This possible connection also needs further assessment. 
Finally, another explanation to our findings may coincide with how breast cancer patients 
cope with their disease and the new life situation, adhere to medical or health advice (102), 
and how they adjust to care and medical treatment. SOC is considered to reflect successful 
coping with stressful situations i.e. characterizes good adaptation to the disease and its 
treatment (36, 37), and predicts adherence to treatment (103-105). Patients with a low SOC 
may not find it comprehensible, manageable and meaningful to comply with for example 
hormonal therapy because of the side effects. A systematic review concluded that many 
breast cancer patients fail to adhere to long term hormonal therapy despite its proven clinical 
efficacy (106). SOC may be related to mortality through to which extent the breast cancer 
patient´s behavior corresponds with medical recommendations, care and treatment. 
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5.3 METHODOLOGICAL CONSIDERATIONS, STRENGTHS AND LIMITATIONS 
Strengths of this studies are, the clinical setting, the use of a large sample, a longitudinal 
prospective data design with a 3-year follow-up regarding SOC (study I), and a median of 10-
year follow-up regarding progress and mortality (study II). Particularly, the reliability of 
registers (66, 67) (the National Cancer Registry (65) and Cause of Death Registry (6)) used. 
Both studies had a high response rate of 75% (study I) and 87% (study II) of the participants. 
Certain shortcomings and limitations of the current study should be considered when 
interpreting the results. Firstly, no power analysis was preformed, as the aim was to evaluate 
any type of arm morbidity after different types of axillary surgery. The representativeness of 
the sample needs to be considered. At the time of data collection (1999-2004), the number of 
patients declining participation and their reasons for declining were not recorded. This could 
contribute to a selection bias. However, the sample is representative regarding age, tumor 
stage (according to TNM classification) and treatment according to the Regional Breast 
Cancer Registers from each region at the time of inclusion (2), and the sample is also 
representative regarding breast cancer mortality in Sweden (7). The mean value of SOC is 
similar to other studies that include women with breast cancer (21, 33).  
Second, at the time of inclusion clinical practice focused more on prognostic than on 
predictive markers. Estrogen and progesterone receptor status were the only predictive 
markers used and HER2 status was not routinely assessed during the study period. To what 
extent that information may had an impact on treatment decisions, disease progression and 
survival, for the included patients remains unclear.  
Third, the AUC indicated that SOC is a rather strong predictor but as a single predictor not 
very sensitive or specific. On the other hand, there exists no predictor that solely can explain 
the complexity of survival in any model. Our conclusion is that SOC is not the only predictor 
of survival but an important one. 
 30 
  
  31 
6 CLINICAL IMPLICATION 
These findings are essential to consider in clinical practice, during the initial planning of care 
and treatment and during the follow-up period. The fact that patients with apparently similar 
tumors at the time of diagnosis differ significantly in time to tumor progression and in 
survival, implies that the determinants of outcome could be broader than initially assumed in 
the purely medical framework. The SOC concept could be used as an adjunct in patient care 
to achieve specific post-treatment goals for example treatment compliance, reduced 
morbidity vs. enhanced health related quality of life and prolonged survival. The SOC scale 
could thus be a complement for assessment of women at risk when designing individual 
nursing and treatment plans before the start of the treatment period.   
7 FUTURE PERSPECTIVES 
Future research is warranted both to confirm our results and to replicate the present findings 
in another population with more advanced disease. Furthermore, research is needed to assess 
SOC´s predictive value on progress and mortality also in other diseases.  
Additionally, potential links between SOC and breast cancer progression and mortality such 
as physiological stress response, depressive symptoms and patient´s behavior pattern need to 
be further explored. 
Additional work is needed to understand how the SOC concept can improve the health 
trajectory, particularly in the areas of seeking help and support, adherence and identifying 
best practices for enhancing coping skills during and after the treatment period.  
Although survival is the most important measure of outcome in breast cancer, it would be 
valuable to assess SOC and its association with health related quality of life, distress and the 
burden of treatment-related side effects. Interventions such as psychosocial support to those 
with a low SOC could be assessed before the start of the treatment period. 
8 CONCLUSIONS 
The present research contributes to further knowledge of the SOC scale´s stability and its 
predictive value with regards to progression and mortality in breast cancer patients. 
1. The SOC scale and the underlying construct is stable over time and can thus be used at 
different assessment periods in women with primary breast cancer 
2. The longitudinal factor analysis demonstrates that the SOC scale is a suitable instrument 
for measuring the overall ability to cope with life strain, in women with breast cancer.  
3. SOC has a predictive value for disease progression, breast cancer caused mortality and for 
all-cause mortality among women with primary breast cancer and could thus be a 
complement for assessment of women at risk. 
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9 SUMMARY IN SWEDISH/SAMMANFATTNING PÅ 
SVENSKA 
Bröstcancer har i genomsnitt ökat med 1.4% årligen under de senaste decennierna. Tidig 
diagnos och utveckling av nya behandlingsmetoder är de främsta orsakerna till en ökad fem- 
och tioårs överlevnad. De biologiska faktorer som påverkar sjukdomsutveckling och 
mortalitet i cancer är väl studerade. De övergripande förhållningssätt som påverkar kliniska 
resultat hos bröstcancerpatienter är förhållandevis mindre studerade. Begreppet känsla av 
sammanhang (KASAM) återspeglar en persons orientering i livet och beskrevs för att 
förklara varför människor förblir friska under tider av stora påfrestningar och ser ett 
sammanhang vid svåra upplevelser eller situationer. KASAM är mätt med ett formulär 
bestående av 13 påståenden som mäter de grundläggande KASAM komponenterna: 
begriplighet, hanterbarhet och meningsfullhet. Högre KASAM värden indikerar en högre 
känsla av sammanhang. 
Huvudsyftet med forskningsprojektet var dels att utvärdera KASAM-skalans stabilitet och 
dels att studera dess prediktiva värde avseende sjukdomsprogress och mortalitet hos patienter 
med bröstcancer. Studiepopulationen utgjordes av patienter som rekryterats till en 
multicenterstudie avseende armmorbiditet vid olika typer av bröstkirurgi. Kvinnorna 
besvarade KASAM-formuläret preoperativt samt 1, 2 och 3 år postoperativt. Sjuttiofem 
procent och 87 procent av ursprungskohorten inkluderades i de båda studierna. Resultaten av 
studie I ger stöd för KASAM skalans stabilitet över tid (ICC 0.68, effektstorlek 0.06). 
Tvärsnittsfaktoranalysen visade att en modifierad tre-faktor modell och en andra ordningens 
faktor modell uppfyllde kriterierna för ”goodness-of-fit”. Den longitudinella modifierade 
andra ordningens faktormodell bekräftade även KASAM skalans innehållsmässiga stabilitet 
med en acceptabel ”goodness-of-fit”. 
Resultaten av studie II visar att patienter med en hög KASAM hade en 60% lägre risk för 
bröstcancerprogress och en 80% lägre risk för död än patienter med en låg KASAM under en 
medianuppföljningstid på 10 år. Mortalitetsrisken minskade med 2.3% för varje enhetsökning 
av KASAM (bröstcancermortalitet HR, 0.98; 95 % CI, 0.96–0.99 och mortalitet oavsett orsak 
HR, 0.98; 95 % CI, 0.96–0.99). Efter justering för andra prediktiva faktorer minskade risken 
för bröstcancermortalitet med 1.7% och risken för mortalitet oavsett orsak med 1.5%. Risken 
för sjukdomsprogress minskade med 1.4% för varje enhet ökning av KASAM (HR, 0.99; 95 
% CI, 0.97–1.00). Efter justering för prediktiva faktorer, var minskningen 0.7%. 
Sammanfattningsvis är KASAM-skalan och dess underliggande struktur stabil över tid hos 
kvinnor med bröstcancer. Utöver detta har KASAM ett prediktivt värde för 
sjukdomsprogress, död i bröstcancer och för död oavsett orsak, hos kvinnor med bröstcancer. 
KASAM-skalan skulle kunna användas för att identifiera högriskpatienter i olika skeenden av 
bröstcancerprocessen.  
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10 APPENDIX 
10.1 SOC-13, SWEDISH VERSION 
 
SOC 
 
 
 
 
Frågorna gäller hur Du upplever vanliga situationer som är viktiga för Dig. 
 
 
För varje fråga finns det siffror. Din uppgift är att ta ställning till vilken siffra som bäst motsvarar 
vad Du känner. Rita en ring omkring den siffran. 
 
 
Här är ett exempel! 
 
9. Händer det att Du har känslor som Du helst inte vill kännas vid?  
 
mycket ofta     1       2       3       4       5       6       7     mycket sällan  
                                                                                     eller aldrig  
 
 
Det är viktigt att Du svarar som Du vanligtvis känner och inte hur det är just nu.  
Arbeta snabbt och fundera inte länge på någon fråga. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Översatt från Antonovskys frågeformulär (The Sense of Coherence Questionnarie) 
Av H. Björvell och A. Langius, 1987. 
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1. Har Du en känsla av att Du faktiskt inte bryr Dig om vad som pågår 
runt omkring Dig?  
 
mycket sällan     1       2       3       4       5       6       7     mycket ofta  
eller aldrig  
 
2. Har det hänt att Du förvånats över beteendet hos personer som Du trodde Du 
kände?  
 
har aldrig hänt     1       2       3       4       5       6       7     har hänt mycket ofta  
 
3. Har det hänt att människor som Du litade på har gjort Dig besviken?  
 
har aldrig hänt     1       2       3       4       5       6       7     har hänt mycket ofta  
 
4. Tycker Du att Ditt liv fram till nu…  
 
helt har saknat     1       2       3       4       5       6       7     haft klara mål  
mål och mening                                                              och stor mening  
 
5. Har Du en känsla av att Du blir orättvist behandlad?  
 
mycket ofta     1       2       3       4       5       6       7     mycket sällan  
                                                                                     eller aldrig  
 
6. Har Du känslan av att vara i en obekant situation utan att veta vad Du skall 
göra?  
 
mycket ofta     1       2       3       4       5       6       7     mycket sällan  
                                                                                     eller aldrig  
  
7. Är Dina dagliga sysslor…  
 
en källa till djup     1       2       3       4       5       6       7     en plåga och en leda glädje och                                                                             
tillfredställelse  
 
8. Har Du mycket motstridiga känslor och idéer?  
 
mycket ofta     1       2       3       4       5       6       7     mycket sällan  
                                                                                     eller aldrig  
 
 
9. Händer det att Du har känslor inom Dig som du helst inte vill känna?  
 
mycket ofta     1       2       3       4       5       6       7     mycket sällan  
                                                                                     eller aldrig  
 
10. Många människor – även de med stark självkänsla – kan känna sig helt  
misslyckade i vissa situationer. Hur ofta har Du känt så?  
 
aldrig     1       2       3       4       5       6       7     mycket ofta  
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11. När någonting har hänt, har Du i allmänhet upptäckt att Du..  
 
över- eller under-     1       2       3       4       5       6       7     såg saker i dess  
värderar betydelsen                                                               rätta proportioner  
av vad som hände  
 
12. Hur ofta känner Du att det inte finns någon mening med Dina dagliga sysslor?  
 
mycket ofta     1       2       3       4       5       6       7     mycket sällan  
                                                                                     eller aldrig  
 
13. Hur ofta har Du känslor som Du är osäker på att kunna behärska?  
 
mycket ofta     1       2       3       4       5       6       7     mycket sällan  
                                                                                     eller aldrig  
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”Om jag vill lyckas med att föra en människa mot ett bestämt mål, måste jag först finna 
henne där hon är och börja just där. Den som inte kan det lurar sig själv när hon tror att hon 
kan hjälpa andra.”   
Søren Kirkegaard 
